The ALS Association: Home


Excerpted from the website:

The ALS Association has awarded Cambria Biosciences a $3.5 million contract to develop new drug compounds for treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease. This partnership builds on previously funded efforts with Cambria to develop unique neuroprotective drug compounds that prevent cell death caused by misfolded proteins that aggregate together within the cell. Mutant copper-zinc superoxide dismutase, or SOD1, is a protein that is misfolded to form aggregates in the motor neurons of some people with inherited forms of ALS.
read more




6627 S 191st Pl
Kent WA 98032 US


ALS Association Evergreen Chapter
+1 425 656 1650

Additional Information

Related Domains

External Links

Domain Resolution

This domain resolves to the following IP addresses:

Retrieved from ""